Carl Zeiss Meditec Reports Modest Revenue Growth for Q1 2024/25

Carl Zeiss Meditec AG reported a slight increase in revenue for the first quarter of fiscal year 2024/25. Revenue reached €490.5 million, a 3.2% increase from the previous year. However, the operating result (EBITA) fell to €35.2 million, with a reduced margin of 7.2%. This decline is attributed to a high comparative base and a shift to new product models.

The Ophthalmology unit saw a 7.1% revenue increase, driven by the DORC acquisition, while Microsurgery experienced a 7.8% decline. Regional performance varied: EMEA and Americas saw growth, while APAC faced a revenue fall, notably in China and Japan.

CEO Dr. Markus Weber remains optimistic about organic growth prospects, supported by new product approvals and improving order backlogs.